Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
Related Experiment Video
Updated: May 7, 2026
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Louise M Moist1, Stéphan Troyanov, Colin T White
1Department of Medicine and Epidemiology, Kidney Clinical Research Unit Western University, London, Ontario, Canada.
Insights
Canadian nephrologists offer commentary on anemia management guidelines for chronic kidney disease patients. They support iron therapy trials but find insufficient evidence for upper ferritin and transferrin saturation thresholds, advising caution with erythropoiesis-stimulating agents.
Area of Science:
- Nephrology
- Hematology
- Clinical Practice Guidelines
Background:
- The Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guideline provides a framework for managing anemia in chronic kidney disease (CKD).
- The Canadian Society of Nephrology (CSN) offers commentary on the KDIGO guideline's applicability within the Canadian healthcare system.
Purpose of the Study:
- To provide a Canadian perspective on the KDIGO 2012 anemia management guideline for CKD patients.
- To comment on specific KDIGO guideline statements regarding iron therapy, hemoglobin targets, and erythropoiesis-stimulating agent (ESA) use.
Main Methods:
- Review and commentary on 11 specific statements from the KDIGO 2012 anemia guideline.
- Analysis of evidence supporting iron therapy, ferritin, transferrin saturation, and hemoglobin targets in CKD anemia.
Main Results:
- Agreement on initiating iron therapy trials when desired reduction in ESA or transfusion is needed, with specific transferrin saturation (>30%) and ferritin (>500 μg/L) levels.
- Disagreement on upper thresholds for ferritin and transferrin saturation due to insufficient evidence.
- Agreement on initiating erythropoiesis-stimulating agent (ESA) treatment at hemoglobin (Hb) 90-100 g/L, but recommending an acceptable Hb range of 95-115 g/L (target 100-110 g/L) with caution.
- Recommendation for cautious ESA use in patients with active malignancy or history of stroke/malignancy, suggesting initiation at Hb 90 g/L and aiming for 90-105 g/L.
Conclusions:
- The CSN commentary aligns with KDIGO on several points but highlights areas needing further evidence, particularly upper limits for iron parameters.
- Revised hemoglobin targets and cautious approach to ESA therapy are recommended for specific CKD patient populations.
- Clinicians should consider the level of evidence and individualize treatment based on patient factors and the full KDIGO guideline.
Abstract:
The KDIGO (Kidney Disease: Improving Global Outcomes) 2012 clinical practice guideline for anemia management in patients with chronic kidney disease provides the structural and evidence base for the Canadian Society of Nephrology commentary on this guideline's relevancy and application to the Canadian health care system. While in general agreement, we provide commentary on 11 of the 61 KDIGO guideline statements. Specifically, we agreed that a therapeutic trial of iron is appropriate in cases in which a reduction in erythropoiesis-stimulating agent (ESA) dosage or avoidance of ESA and transfusion is desired, transferrin saturations are >30%, and ferritin concentrations are >500 μg/L. However, we concluded that there is insufficient evidence to support an upper target or threshold for ferritin and transferrin saturation levels. We agree with the initiation of ESA treatment when hemoglobin (Hb) level is 90-100 g/L; however, we specifically state that an acceptable range for Hb level is 95-115 g/L, with a target of 100-110 g/L, and add caution to individualization above this range due to concerns regarding the safety of ESAs. We agree that ESAs should be used with considerable caution in patients with active malignancy, history of stroke, or history of malignancy, and we suggest initiating ESA therapy at Hb level of 90 g/L and to aim for a Hb level in the range of 90-105 g/L. The reader is encouraged to note the level of evidence and review the entire KDIGO anemia guideline to interpret the guideline statements and commentary appropriately.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:18Chronic Kidney Disease IV: Nursing Management
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:20Acute Kidney Injury V: Interprofessional Care